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Abstract
Integrative analysis of gene dosage, expression, and ontology (GO) data was performed to discover driver genes in the
carcinogenesis and chemoradioresistance of cervical cancers. Gene dosage and expression profiles of 102 locally advanced
cervical cancers were generated by microarray techniques. Fifty-two of these patients were also analyzed with the Illumina
expression method to confirm the gene expression results. An independent cohort of 41 patients was used for validation of
gene expressions associated with clinical outcome. Statistical analysis identified 29 recurrent gains and losses and 3 losses
(on 3p, 13q, 21q) associated with poor outcome after chemoradiotherapy. The intratumor heterogeneity, assessed from the
gene dosage profiles, was low for these alterations, showing that they had emerged prior to many other alterations and
probably were early events in carcinogenesis. Integration of the alterations with gene expression and GO data identified
genes that were regulated by the alterations and revealed five biological processes that were significantly overrepresented
among the affected genes: apoptosis, metabolism, macromolecule localization, translation, and transcription. Four genes on
3p (RYBP, GBE1) and 13q (FAM48A, MED4) correlated with outcome at both the gene dosage and expression level and were
satisfactorily validated in the independent cohort. These integrated analyses yielded 57 candidate drivers of 24 genetic
events, including novel loci responsible for chemoradioresistance. Further mapping of the connections among genetic
events, drivers, and biological processes suggested that each individual event stimulates specific processes in
carcinogenesis through the coordinated control of multiple genes. The present results may provide novel therapeutic
opportunities of both early and advanced stage cervical cancers.
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Introduction
Cervical cancer is one of the most common malignancies
affecting women worldwide and a major cause of cancer death for
women globally [1]. Radiotherapy combined with cisplatin is the
treatment of choice at the locally advanced stages [2]. Improved
therapy is needed, since more than 30% of the patients show
progressive disease within 5 years after diagnosis and treatment
related side effects to organs within the pelvis are frequent. Tumor
stage, size, and lymph node involvement are the most powerful
markers of aggressive disease, but do not fully account for the
observed variability in outcome and are not biologically founded.
A better handling of the disease may be provided by the discovery
of efficient biomarkers for therapeutic planning and intervention,
but requires more insight into the mechanisms underlying cervical
carcinogenesis and treatment relapse.
During carcinogenesis, genetic and epigenetic alterations drive
the evolution of tumor towards increased malignancy and
treatment resistance. The changes enable tumor cells to overcome
microenvironmental constraints, sustain proliferation, and invade
adjacent tissues and distinct organs [3–5]. Gene dosage alterations
like gains and losses regulate the expression of genes and are
motive forces for this evolution [6,7]. Tumor cells bearing an
increasing number of gains and losses successively emerge and are
selected for based on the growth advantage caused by the genetic
changes. Discovery and functional assessment of gene dosage
alterations involved in carcinogenesis are therefore essential for
understanding the biology of the disease.
At the locally advanced stages of cervical cancer, numerous
gene dosage alterations and severe aneuploidy are frequently seen
[8–10]. Moreover, pronounced intratumor heterogeneity in the
gains and losses exists within the tumors, reflecting a high genetic
instability [9]. The consequences of these alterations for the tumor
phenotype are difficult to predict, since large chromosomal regions
involving multiple genes are generally affected and some
aberrations may be random events without biological significance
[11]. Genome wide screening of DNA copy numbers in a decent
number of patients enables identification of recurrent gene dosage
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alterations associated with the clinical outcome [12], which are
likely to be important in carcinogenesis and treatment resistance.
Combining the data with expression profiles of the same tumors
reveals the genes that are regulated primarily by the genetic
events. The potential of this integrative strategy was recently
demonstrated in a study on 15 early stage cervical cancers, where
genes affected by aberrations on 1q, 3q, 11q, and 20q were
reported [13]. Genetic events promoting tumor evolution and
treatment resistance have, however, not been explored on a
genome wide scale, and their biological meaning has not been
addressed.
The present work was conducted to discover candidate driver
genes and assess their function in the carcinogenesis and
chemoradioresistance of cervical cancers. Genome wide screening
of DNA copy numbers and expressions was performed in 102
patients with locally advanced disease. Of these, pairwise data
were available for 95 patients. Reliable comparison of gains and
losses across the patients was ensured by using the tumor ploidy, as
determined by flow cytometry, and the GeneCount method to
correct for the normal cell content of the samples and extract the
absolute copy numbers and thereby the gene dosages [14]. The
use of GeneCount also enabled mapping of the intratumor
heterogeneity in the gene dosage alterations, providing informa-
tion of the chronological order in which they had occurred during
tumor evolution [14]. The recurrent gene dosage alterations, the
alterations associated with outcome after chemoradiotherapy, and
the genes that were regulated by these alterations were identified.
Further analysis of gene ontology (GO) categories [15] was
performed to identify biological processes that were overrepre-
sented among the affected genes and therefore probably regulated
by the gene dosage alterations. Such large scale and combined
genomic, transcriptional, and functional analysis is powerful in
detection of driver genes and their biological meaning, but has not
been presented before. We demonstrate the potential of this
approach by the identification of five biological processes in
carcinogenesis that were associated with recurrent and predictive
gains and losses of a set of genes. The set included four genes
within the predictive losses for which repressed expression was
related to poor outcome in the patient group and in an
independent cohort of 41 patients. The genes are candidate
drivers of the genetic events and novel biomarkers of cervical
cancers.
Results
Recurrent Gene Dosage Alterations
Cervical cancer patients subjected to curative chemoradiother-
apy were included in the study (Table 1). Most cases were
squamous cell carcinoma and human papillomavirus (HPV)
positive. Aneuploidy was seen in about half of the tumors,
including some of the adenosquamous carcinomas and HPV
negative cases (Figure S1A, S1B). Based on 97 patients, we
generated an absolute gene dosage profile of the cancer genome by
the use of array comparative genomic hybridization (aCGH) and
Author Summary
Genetic gains and losses, i.e. changes in gene dosages, are
common abnormalities of human cancers. Discovering
these defects and understanding the biological meaning
can lead to improved therapeutic opportunities. This
paper reports a large scale screening of gene dosage
alterations in cervical cancer and gives a broader
exploration of the expression and function of genes with
gains or losses. We have focused on the most frequent
gene dosage alterations and the alterations associated
with survival after chemoradiotherapy, since these defects
are likely to be of major importance for developing
disease. The most notable finding was the discovery of a
set of biological processes that are known hallmarks of
cancer and were associated with gains and losses of
specific genes. Moreover, novel loci associated with
chemoradioresistance independent of existing clinical
markers were found, and the genes involved were
depicted. Our results indicated that gene dosage alter-
ations play a causative role in the carcinogenesis and
chemoradioresistance of cervical cancer and pinpointed
candidate biomarkers of the disease.
Table 1. Patient and tumor characteristics.
Characteristic
Basic cohort
(n=102)
Validation
cohort (n=41)
Histology (n)
Squamous 96 40
Adenocarcinoma 1 0
Adenosquamous carcinoma 5 1
HPV status (n)
a,b
HPV16 65 35
HPV18 7 0
HPV16+18 11 1
HPV other 10 4
HPV negative 8 1
FIGO stage (n)
1B 6 2
25 7 2 7
33 5 9
4A 4 3
Tumor size
c: vol (cm
3)
d, diameter (cm)
e
Median 45.1, 4.4 36.6, 4.1
Range 2.8–321, 1.8–8.5 8.7–192, 2.5–7.2
Pelvic lymph node status
c (n)
Positive 37 12
Negative 65 29
Age (years)
Median 56 55
Range 28–85 25–81
Observation time (months)
Median 42 31
Range 21–71 24–46
Relapse 32 12
aPCR on DNA was performed, using the primers listed in [9]. The products were
detected by polyacrylamide gel electrophoresis or the Agilent DNA 1000 kit
(Agilent Technologies Inc., Germany).
bHPV status was not determined for one patient in the basic cohort due to lack
of DNA for analysis.
cTumor size and lymph node status were determined from pretreatment
magnetic resonance (MR) images.
dVolume was calculated based on 3 orthogonal diameters (a,b,c) as (p/6)*abc.
eDiameter was calculated from tumor volume (4p/3)*r
3.
doi:10.1371/journal.pgen.1000719.t001
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affected with gains and losses, however, some regions were more
frequently found to be aberrant than others (Figure 1B). Clustering
of the patients based on gene dosages revealed no clear groups
with characteristic aberrations.
The recurrent gains and losses were identified by considering
both the amplitude and frequency of each alteration in Figure 1B
[16]. Hence, a larger weight was given to high-amplitude events
that are less likely to be random aberrations without biological
significance. The recurrent alterations comprised more than 42%
of the genome, and consisted of 14 regions (528 Mb) with gain and
15 (734 Mb) with loss (Figure 1C). Most of these alterations were
also seen in the adenosquamous carcinomas and the HPV
negative tumors (Figure S1C, S1D). The most common alterations
were gain on 1q, 3q, 5p, 20q, and Xq and loss on 2q, 3p, 4p, 11q,
and 13q, each involving 44–76% of the patients (Figure 1C,
Table 2). High level amplification (seven regions) and homozygote
deletion (six regions) helped to depict the peak of five recurrent
gains and two recurrent losses (Table 2, Table S1). The frequency
of the homozygote deletions was low (1–3%, Table S1), and none
Figure 1. Gene dosage alterations of locally advanced cervical cancers. (A) Absolute gene dosage profile of 97 patients. Patients are shown
in columns and gene dosages are ordered by DNA location in rows. The color scale ranges from green (loss) through black (neutral) to red (gain). Grey
indicates missing values. (B) Frequency of patients with gains (red) and losses (green) along chromosome 1 to X for the patients in (A). Gene dosage
alterations above 1.1 and below 0.9 were classified as gains and losses, respectively. (C) Score of recurrent gains (red) and losses (green) along
chromosome 1 to X for the patients in (A). Peak regions, defined in Table 2, are shown in darker colors. (D) Intratumor heterogeneity in gene dosage
alterations along chromosome 1 to X for the patients in (A). The heterogeneity index is shown for gains (above the zero line) and losses (below the
zero line) separately, and was calculated as the number of heterogeneous cases relative to the total number of cases with alteration at each DNA
location. The peak regions shown in (C) are marked in red (recurrent gains) and green (recurrent losses). The predictive losses are indicated in light
blue.
doi:10.1371/journal.pgen.1000719.g001
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Peak region
a Peak region
a Freq.
b
Max./min. gene
dosage
c Correlating genesd
(Cytoband) (MB) (%) (copy no.)
Recurrent gain
1p36.21-pter 0–14.6 38 2 (4) SLC35E2, UBE4B, AGTRAP
1p32.1-p34.3 37.3–59.9 40 2 (4) C1orf149, YRDC, RLF, EBNA1BP2, TACSTD2
1q21.1-q22 148.0–153.7 61 2.5 (6) SF3B4, ENSA, GOLPH3L, ARNT, LASS2, ANXA9, POGZ, CGN, SNX27, C1orf77, ILF2,
DENN4B, SLC39A1, UBE2Q1, EFNA1, KRTCAP2, MUC1, FDPS
3q26.1-qter
e 166.2–199.5 75 4.5 (9) PDCD10, PHC3, ZNF639, FXR1, PARL, DVL3, ABCF3, ALG3, EIF4G1, SFRS10, DGKG,
EIF4A2, RFC4, CCDC50, PPP1R2, PAK2, NCBP2, DLG1, BDH1, FLYTTD1
5p15.2-pter
e 1.0–12.1 47 4 (15) CLPTM1L , MED10, FASTKD3, CCT5, DAP
8q24.13-22 125.7–134.1 37 2 (4) None
8q24.3-qter 144.5–146.3 38 2 (4) TSTA3, FAM83H, CYC1
9p24.1-2
e 2.7–6.0 22 13.5 (27) KIAA0020, RCL1
9q34.2-qter 135.6–138.2 35 3.5 (7) MRPS2
11q22.1-2
e 100.2–102.0 14 36 (72) YAP1, BIRC3, BIRC2
19q13.11-qter 40.3–63.8 36 10 (29) SPINT2, PSMD8, CAPN12, MRPS12, RPS16, AP2S1, KDELR1, NUP62, ATF5, NKG7,
ZNF787
20q11.21-22
e 30.0–33.0 45 3.4 (9) POFUT1, KIF3B, MAPRE1, SNTA1, EIF2S2, AHCY
Xp11.22-pter
f 0–54.1 38 2.5 (5) SLC25A6, CD99, ARSD, PNPLA4, PRPS2, PIR, CXorf15, PHKA2, PDHA1, RPS6KA3,
PRDX4, EIF2S3, USP9X, DDX3X, NDUFB11, UBA1, EBP, PLP2, JARID1C, SMC1A,
HUWE1
Xq28-qter 148.5–154.9 47 4 (8) NSDHL, BCAP31, IDH3G, IRAK1, TAZ, LAGE3, UBL4A, FAM34, MTCP1
Recurrent loss
2q33.3-qter 206.2–243.0 54 0.26 (1) NDUFS1, SPAG16, MREG, SMARCAL1, AAMP, WNT10A, ZFAND2B, ANKZF1,
STK11IP, FARSB, ACSL3, HRB, SP100, EIF4E2, COPS8, HDAC4, MTERFD2, PPP1R7
3p12.3-p14.2 60.9–81.6 61 0.26 (1) RYBP, GBE1
4p13-p16.1 8.3–42.3 58 0.42 (1) WDR1, UBE2K, PDS5A
5q13.2
g 67.4–71.7 38 0 (0) SMN2
5q14.2-q15 82.5–96.9 35 0.5 (1) COX7C, TTC37, GLRX
6q12-q23.2 67.0–132.9 42 0.43 (1) LMBRD1, MYO6, HMGN3, SYNCRIP, MAP3K7, CCNC, C6orf203, FOXO3, AMD1,
HDAC2, NT5DC1, DSE, NUS1, ECHDC1
7q34-qter 139.3–158.8 35 0.43 (1) PDIA4
8p12-pter 0–31.9 32 0.34 (1) XPO7, BIN3, BNIP3L, EPHX2, CCDC25, DCTN6, PPP2CB
10q23.31
g 88.2–92.1 38 0 (0) None
11p14.3-pter 0–24.4 40 0.5 (1) COPB1, PSMA1, GTF2H1, TSG101
11p12 37.8–40.2 37 0.5 (1) None
11q22.3-qter 105.1–134.5 63 0.35 (1) PPP2R1B, C11orf57, TIMM8B, REXO2, C11orf60, TRAPPC4, H2AFX, POU2F3,
ARHGEF12, SC5DL, ZNF202, CHEK1, APLP2, ZBTB44, SNX19
13q12.2-q21.32 27.5–67.4 46 0.33 (1) ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B
17p11.2-pter 0–19.1 38 0.27 (1) SPAG7, MPDU1, LSMD1, CYB5D1, COPS23
21q21.1-3 18.3–28.6 35 0.28 (1) ATP5J
Predictive loss
3p11.2-p14.1 67.0–87.6 58 0.26 (1) RYBP, GBE1
13q13.1-q21.1 30.0–56.5 46 0.41 (1) ALG5, FAM48A, COG6, KIAA1704, GTF2F2, MED4, RNASEH2B
21q22.2-3 38.0–46.4 23 0.28 (1) PCP4, RIPK4, PDXK
aPeak region of the recurrent gains and losses is the minimum shared region surrounded by at least three patients. In cases of recurrent high level amplification or
homozygote deletion, this event determines the peak region. Peak region of the predictive losses is the region selected by LASSO.
bFrequency is the median percentage of tumors with the alteration.
cGene dosage is absolute DNA copy number divided by ploidy. Maximum (gain) or minimum (loss) gene dosage and corresponding copy number are listed.
dGenes within the peak region showing a correlation between gene dosage and expression are ordered by DNA location.
eRecurrent high level amplification detected within recurrent gain. Peak region is the region with more than 25% higher amplitude than surrounding region.
fProbably two different peak regions.
gHomozygote deletion within recurrent loss. Peak region is the region with a gene dosage of zero.
doi:10.1371/journal.pgen.1000719.t002
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is therefore probably not a common mechanism of gene regulation
in cervical cancers, in contrast to the highly frequent heterozygote
deletion. The highest gene dosage of 36 was found in a diploid
tumor with a copy number of 72 on 11q22.1-2 (Table 2).
Intratumor heterogeneity of the recurrent alterations.
Intratumor heterogeneity in one or more of the gene dosage
alterations was seen in about half of the patients [14]. The ploidy
and genetic alterations of the heterogeneous tumors were similar
to that of the homogeneous ones (Figure S2). It is reasonable to
assume that homogeneous alterations have emerged before the
heterogeneous ones during tumor evolution [9]. To order the
recurrent alterations chronologically in relation to the less
common alterations, we therefore mapped the intratumor
heterogeneity along the chromosomes based on the absolute
data achieved with GeneCount [14]. The heterogeneity was low
for the recurrent alterations compared to others, like gain on 2q
and 13q and loss on 1q, 19q, and 20q (Figure 1D). The recurrent
aberrations had therefore probably occurred prior to many of
these less common events.
Gene Dosage Alterations in Relation to Outcome after
Chemoradiotherapy
Gene dosage alterations responsible for poor clinical outcome
may not be as common as the recurrent ones. All alterations in
Figure 1B were therefore included in the survival analysis. The
LASSO method identified three regions with loss, 3p11.2-p14.1,
13q13.1-q21.1, and 21q22.2-3, which jointly showed the strongest
association to progression free survival (Table 2). The 3p11.2-
p14.1 and 13q13.1-q21.1 regions overlapped with the recurrent
3p12.3-p14.2 and 13q12.2-q21.32 losses, whereas the predictive
loss of 21q22.2-3 was distal of the recurrent loss of 21q21.1-3. The
predictive losses were not correlated and were related to poor
outcome also when analyzed separately (Figure 2A–2C). The
intratumor heterogeneity of the losses was low and similar to that
of the recurrent losses (Figure 1D).
Most patients had more than one of the predictive 3p, 13q, and
21q losses. We therefore investigated whether there was an
increased risk of relapse in cases of two or three losses. Kaplan-
Meier plotsforpatients withdifferent combinationsof the predictive
losses revealed three major groups with different outcome (Figure
S3). Patients without any of the losses had a low risk of relapse and a
survival probability of 91% (Figure 2D). Patients with 3p and/or
13q loss, without 21q loss, had an intermediate survival probability
of 68%, whereas those with 21q loss had the lowest survival
probability of 44%. The risk of relapse therefore seemed to be
particularly high when loss of 21q22.2-3 was involved.
The predictive impact of the 3p, 13q, and 21q losses were
assessed by multivariate analysis together with tumor size, stage,
and lymph node status. Histological type, HPV status, and
heterogeneity status showed no correlation to outcome in
univariate analysis and were therefore not included. The losses
and tumor size had independent predictive value (Table 3),
showing that the gene data contained information of the
progression free survival that was not covered by tumor size.
Since tumor size is a strong predictor (Figure 3A), we also
investigated the predictive impact of the three losses for small and
large tumors separately. About 20% of the patients with tumor size
less than the median had relapse and all of them had one or more
of the losses (Figure 3B). In the cases of tumors larger than the
median, about 47% of the patients progressed and all except two
of them had one or more of the losses (Figure 3C). None of the
patients with loss involving 21q were disease free after 28 months,
suggesting a particularly high risk of relapse in cases of a large
Figure 2. Gene dosage alterations and outcome after chemor-
adiotherapy. Kaplan-Meier curves of progression free survival for
cervical cancer patients with (green) and without (black) loss of 3p11.2-
p14.1 (A), 13q13.1-q21.1 (B), 21q22.2-3 (C), and for patients with
different combinations of the three losses (D). P-values in log-rank test
and number of patients are indicated. Data of the most significant
genomic clone within each region were used; i.e, BAC clone ID RP11-
118O11 (3p), RP11-408L13 (13q), and RP1-128M19 (21q). Total number
of patients in (A, B) is less than 97 due to missing gene dosage data. (A–
C) The lost DNA region is indicated on the chromosome (left). (D) Group
1: patients without loss of 3p11.2-p14.1, 13q13.1-q21.1, or 21q22.2-3,
group 2: patients with loss of 3p11.2-p14.1 and/or 13q13.1-q21.1, but
not 21q22.2-3, group 3: patients with loss of 21q22.2-3 only or loss of
21q22.2-3 combined with loss of 3p11.2-p14.1 and/or 13q13.1-q21.1.
The groups were determined from data of each possible combination
of the losses (Figure S3).
doi:10.1371/journal.pgen.1000719.g002
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size for patients with and without loss in Figure 3B or in Figure 3C
(data not shown). The gene data therefore enabled identification of
high and low risk patients both in cases of a small and a large
tumor.
Integration of Gene Expression
To find genes regulated by the recurrent and predictive gene
dosage alterations, we used cDNA microarrays and generated a
cancer gene expression profile. The profile was based on 100
patients, including 95 of those analyzed with aCGH. Expression
data were available for 1357 of the about 4000 known genes
within the altered regions, and a significant correlation to gene
dosage was found for 191 of them (Table 2). Several correlating
genes were identified for each region, except for 8q24.13-22,
10q23.31, and 11p12, where no genes were found. Typical
examples of correlation plots are shown in Figure S4. The results
were confirmed with the Illumina gene expression assay on 52
patients. Although the Illumina analysis was based on a lower
number of patients, an excellent correlation between the Illumina
and cDNA data and between the Illumina and gene dosage data
was found for almost all of the genes, as demonstrated in Table S2.
We also performed a second cDNA analysis, including only
tumors with more than 70% tumor cells in hematoxylin and eosin
(HE) stained sections. Totally 179 of the genes (94%) were
identified, suggesting few false positive results due to normal cells
in the samples. The observations supported our conclusion that
the genes in Table 2 were gene dosage regulated. The latter
analysis identified 26 genes that were not depicted when all
patients were considered. These genes were not considered
further, since the results were based on only half of the data set.
Expression of known oncogenes and tumor suppressor genes
within the depicted regions, like MYC (8q24.21), BRCA2 (13q13.1),
RB1 (13q14.2), and TP53 (17p13.1), was not significantly
correlated to gene dosage. These genes are therefore probably
not regulated primarily by gains and losses. The TP53 and RB1
results were consistent with the high frequency of HPV positive
tumors (Table 1).
The predictive losses on 3p and 13q involved the same
correlating genes as the corresponding recurrent ones, whereas
PCP4, RIPK4, and PDXK were correlating genes within the
Figure 3. Gene dosage alterations and outcome after chemor-
adiotherapy for patients with different tumor size. (A) Kaplan-
Meier curves of progression free survival for cervical cancer patients
with tumor size above (green) and below (black) median. Ninety-two
patients with tumor size determined from diagnostic MR images were
included. Median size was 45.1 cm
3, corresponding to a diameter of
4.4 cm. (B,C) Kaplan-Meier curves for patients in (A) with tumor size
below median (B) and above median (C). Group 1: patients without loss
of 3p11.2-p14.1, 13q13.1-q21.1, or 21q22.2-3, group 2: patients with loss
of 3p11.2-p14.1 and/or 13q13.1-q21.1, but not 21q22.2-3, group 3:
patients with loss of 21q22.2-3 only or loss of 21q22.2-3 combined with
loss of 3p11.2-p14.1 and/or 13q13.1-q21.1. The groups were deter-
mined from data of each possible combination of the losses (Figure S3).
P-values in log-rank test and number of patients are indicated.
doi:10.1371/journal.pgen.1000719.g003
Table 3. Cox regression analysis of genetic losses and clinical
variables.
Univariate analysis
a Multivariate analysis
a
Covariate P HR 95% CI P HR 95% CI
Loss of 3p11.2-p14.1
b 0.003 0.27 0.11–0.66 0.018 0.33 0.13–0.83
Loss of 13q13.1-q21.1
b 0.006 0.32 0.14–0.72 0.015 0.35 0.14–0.82
Loss of 21q22.2-3
b 0.004 0.34 0.16–0.71 0.019 0.32 0.12–0.84
Tumor size
c 0.001 4.5 1.9–10.5 0.001 5.5 1.9–15.5
FIGO stage
d 0.004 2.9 1.4–5.9 0.072 - -
Total lymph node status
e 0.030 0.46 0.22–0.93 0.285 - -
aP-value (P), hazard ratio (HR), and 95% confidence interval (CI) are listed.
bSemi-discrete gene dosage data of the most significant genomic clone within
each region were used.
cTumor size was divided in two groups based on the median size of 45.1 cm
3,
corresponding to a median diameter of about 4.4 cm.
dFIGO stage was divided in two groups; 1b–2b and 3a–4a.
eTotal includes pelvic and para aortal lymph nodes.
doi:10.1371/journal.pgen.1000719.t003
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that most probably were involved in development of chemor-
adioresistance, we required that the gene was significantly
associated with clinical outcome both at the gene dosage and
expression level. Moreover, a clear difference in the survival curves
should also be seen in an independent cohort of 41 patients when
based on the Illumina gene expression data. The criteria were
fulfilled for four genes; RYBP and GBE1 on 3p and MED4 and
FAM48A on 13q, which were termed predictive genes (Figure 4).
Two more genes, GTF2F2 and RNASEH2B on 13q, were
correlated to outcome based on the cDNA data, but were not
considered further since the tendency based on the Illumina data
was weak (p.0.15). The relationship to outcome was not strong
enough for PCP4, RIPK4, and PDXK on 21q to be included among
the predictive genes either.
Gene Ontology Analysis
Biological processes associated with the recurrent and predictive
gene dosage alterations were found by comparing the GO
categories of the affected genes with those of all genes in the data
set [15]. One or more biological processes were annotated to 155
of the correlating and predictive genes and to 5824 of all genes.
The categories apoptosis, carbohydrate metabolism, translation,
and RNA-protein complex biogenesis and assembly were
significantly overrepresented among the correlating genes within
the recurrent gains, whereas macromolecule localization, gener-
ation of precursor metabolites and energy, transcription from
RNA polymerase II promoter, and establishment or maintenance
of chromatin architecture were overrepresented among those
within the recurrent and predictive losses (Table 4). Fifty-six genes
were included in the significant categories and were candidate
drivers of the biological processes. In addition, we included the
predictive gene FAM48A, which was not associated to any process
in the GO database, as a potential driver of chemoradioresistance
together with RYBP and MED4 (transcription) and GBE1
(generation of precursor metabolites and energy).
We generated a map to visualize the connections between
genetic events, affected genes, and biological processes (Figure 5).
The processes carbohydrate metabolism and generation of
precursor metabolites and energy were combined in metabolism,
translation and RNA-protein complex biogenesis and assembly
were combined in translation, and transcription from RNA
polymerase II promoter was combined with establishment or
maintenance of chromatin architecture in transcription. The
combined categories were closely related, justifying this strategy.
All but six of the recurrent alterations were associated with a
process and represented in the map. The predictive 3p and 13q
losses were merged with the corresponding recurrent losses, since
the regions overlapped, and linked to metabolism (GBE1) and
transcription (RYBP, MED4) in addition to chemoradioresistance.
The predictive 21q loss was not connected to any known gene, but
associated with chemoradioresistance. The map revealed features
that seemed to be characteristic of recurrent and predictive
alterations in cervical cancer. First, many of the genetic events
were associated with clusters of genes in the same biological
Figure 4. Gene expressions and outcome after chemoradiotherapy. Kaplan-Meier curves of progression free survival for cervical cancer
patients with low (green) and high (black) expression of RYBP (A,E), GBE1 (B,F), MED4 (C,G), and FAM48A (D,H). cDNA data of 100 patients is used in (A–
D), and Illumina data of an independent cohort of 41 patients is used in (E–H) for validation. P-value in log-rank test and number of patients are
indicated. The number of patients in each group was chosen to achieve the largest difference in survival between the groups, approximately
reflecting the number of patients with and without loss in (A–D). Total number of patients is less than 100 in (B) due to missing gene expression data.
doi:10.1371/journal.pgen.1000719.g004
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and three in translation, gain on 5p was linked to tree apoptosis
genes, and loss on 6q was associated with four genes in
transcription. Second, several events, like gain on 3q, 19q, 20q
and loss on 2q, 6, and 11q, were connected to more than one
biological process, either through the regulation of several genes or
because some genes had multiple functions.
Discussion
This work presents the first coupling of gene dosage and
expression profiles in a large sample set of cervical cancers. We
based our study on absolute gene dosages, which are more
sensitive than the commonly used aCGH ratios in detecting gains
and losses and enable comparisons across tumors with differences
in ploidy and normal cell content [14]. This strategy and the large
number of patients ensured reliable identification of recurrent
gene dosage alterations, events associated with clinical outcome,
and their intratumor heterogeneity. Further analysis based on GO
categories provided an objective way of organizing the numerous
correlating genes into biological meaningful information. We
demonstrate a large potential of the integrative approach by the
discovery and functional assessment of candidate driver genes that
represent novel biomarkers of the disease. In particular, novel loci
associated with clinical outcome were identified, providing the first
evidence that gene dosage can be responsible for developing
chemoradioresistance in cervical cancers.
The recurrent gene dosage alterations were consistent with
earlier reports on advanced stage cervical cancer based on
conventional CGH [8,9,17]. However, a more precise definition
of the altered regions was achieved here due to the improved
resolution of the array technique. The high frequency of the
alterations suggests that they play a causative role in carcinogen-
esis. Hence, many of the alterations are common also in other
squamous cell carcinomas, like head and neck cancers [18,19].
Moreover, the recurrent loss on 3p and 13q overlapped with the
losses associated with poor clinical outcome, strengthening the
hypothesis of a central role in tumor evolution. Less frequent
alterations can, however, also be crucial for tumor evolution, as
was demonstrated by the recurrent gain on 11q22 in 14 patients
and predictive loss on 21q in 23 patients.
The low intratumor heterogeneity of the recurrent and
predictive gene dosage alterations indicated that they had
occurred prior to many of the other alterations. The result was
consistent with our previous cervical cancer study based on
conventional CGH [9], showing a homogeneous intratumor
distribution of the frequent gains on 3q, 5p, and 20q and losses
on 3p and 11q14-qter. Moreover, regions overlapping with the 1p,
1q, 3q, 8q, 9q, and 20q recurrent gains and 2q, 3p, 4p, 11q, and
17p losses have been found to be altered in precancerous cervical
intraepithelial lesions [17,20–23], suggesting that the events had
occurred at an early stage. It is therefore likely that the alterations
identified here, and the consequently control of biological
processes and development of chemoradioresistance, emerge early
during carcinogenesis. It should be noted that a low heterogeneity
was seen for some of the less common alterations as well, implying
that they had occurred early. The affected genes in these regions
may also be crucial for tumor evolution, however, other
mechanisms than gene dosage alterations, such as epigenetic
events or mutations, probably play the major role in their
regulation. Moreover, some of the highly heterogeneous alter-
ations may be important for disease progression a later stage, being
a result of the continuing tumor evolution towards increased
aggressiveness.
The gene dosage alterations were associated with specific
biological processes that are closely related to known cancer
Table 4. Biological processes overrepresented among the correlating genes within recurrent and predictive regions.
GO number GO category
No. correlating
genes
No. genes
on the array p-value Correlating genes
Gains
GO: 000815 Biological process 93
a 5824
a
GO: 0006915 Apoptosis 13 (14.0%) 434 (7.5%) 0.026 UBE4B, BIRC2, BIRC3 , ATF5, BCAP31,
CLPTM1L, DAP, FASTKD3, FXR1, NUP62,
PAK2, PDCD10, SLC25A6
GO: 0005975 Carbohydrate metabolism 7 (7.5%) 198 (3.4%) 0.038 PPP1R2, ARNT, PHKA2, POFUT1, PDHA1,
TSTA3, IDH3G
GO: 0006412 Translation 7 (7.5%) 163 (2.8%) 0.015 EIF4G1, EIF4A2, EIF2S2, MRPS12, RPS16,
EIF2S3, MRPS2
GO: 0022613 RNA-protein complex biogenesis and assembly 7 (7.5%) 89 (1.5%) 0.001 EIF4G1, EIF4A2, EIF2S2, EIF2S3,
EBNA1BP2, NCBP2, RCL1
Losses
GO: 000815 Biological process 62
a 5824
a
GO: 0033036 Macromolecule localization 10 (16.1%) 427 (7.3%) 0.022 BIN3, COPB1, COG6, XPO7, HRB, MYO6,
PDIA4, SNX19, TIMM8B, TSG101
GO: 0006091 Generation of precursor metabolites and energy 4 (6.5%) 117 (2.0%) 0.035 ATP5J, COX7C, GBE1, NDUFS1
GO: 0006366 Transcription from RNA polymerase II promoter 10 (16.1%) 357 (6.1) 0.004 RYBP, FOXO3, GTF2F2, GTF2H1, MED4,
MYO6, POU2F3, SMARCAL1, ZNF202,
HDAC4
GO: 0006325 Establishment or maintenance of chromatin
architecture
5 (8.1%) 140 (2.4%) 0.016 DSE, H2AFX, HDAC2, SMARCAL1,
HDAC4
aGenes with GO annotation (biological process).
doi:10.1371/journal.pgen.1000719.t004
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carcinogenesis. Hence, gain of the genes in apoptosis, including
the anti-apoptosis genes BIRC2, BIRC3, and ATF5, can help
carcinoma cells to evade apoptosis [3]. Aberrations of the genes in
metabolism, like gain of ARNT and IDH3G in carbohydrate
metabolism, and loss of COX7C and ATP5J in oxidative
phosphorylation, can be part of a metabolic reprogramming
towards increased glycolysis and decreased mitochondrial function
to meet the high energy demand linked to tumor growth [4]. In
particular, gain of ARNT may increase hypoxia and hypoglycemia
tolerance by signaling through the HIF1A pathway [24]. Loss of
the genes in molecular localization, including HRB and TSG101,
can lead to abnormal protein internalization and recycling and
thereby abrogated degradation of proteins like growth factor
receptors [25,26]. Finally, aberrations of the genes in translation
and transcription, such as gain of the translation initiation factors
EIF4A2, EIF4G1, EIF2S2, and EIF2S3 and loss of the transcrip-
tional repressors HDAC2 and HDAC4, can be a way to control the
formation and activity of essential proteins. The EIF-proteins are
central in adaptation to hypoxia and can stimulate MYC
translation and thereby oncogenic processes like cell proliferation
[27,28]. Improper function of HDAC2 and HDAC4 may also
increase proliferation [29]. Many of the genes, including BIRC2,
BIRC3, ATF5, NUP62, FASTKD3, IDH3G, and POFUTI, have
been found to be regulated by gains or losses in previous cervical
cancer studies [30–33]. Our findings link each gene to one or more
specific biological processes, and thereby indicate the functional
meaning of the genetic events in carcinogenesis.
Loss and down regulation of GBE1 and RYBP on 3p and MED4
and FAM48A on 13q were associated with poor clinical outcome,
suggesting that the genes are drivers of chemoradioresistance. The
mechanisms underlying these findings and possible associations to
known aggressive phenotypes like hypoxia and rapid proliferation
[34–36] are not clear, but a tumor suppressor function of the genes
has been indicated. GBE1, which plays a role in carbohydrate
metabolism, has been found to be down regulated in ovarian
cancers [37]. Loss of the transcriptional repressor RYBP may impair
death receptor-mediated apoptosis [38,39], and the encoded
protein has been shown to be down regulated in many tumor
types, including cervical cancer [40]. Loss of the transcriptional
activators MED4 mayimpair transcriptionof geneswithanti-cancer
effect, like the vitamin D receptor [41,42]. The function of FAM48A
is less clear, but some studies indicate that loss of this gene can
promote aggressiveness. Hence, FAM48A is required for activation
of the MAPK p38 pathway [43], which represses cell proliferation
[44]. We found no candidate driver gene of chemoradioresistance
within the predictive loss on 21q. Only a few tumor suppressor
genes have been identified in this region. One candidate is the
transcriptional regulator PRDM15, which was not included in our
cDNA data set [45]. Our data showed, however, no correlation
between PRDM15 expression, assessed with the Illumina method in
52 patients, and gene dosage (data not shown), suggesting that the
gene is not regulated by genetic loss. Further investigation with
denser microarrays or possibly microRNA screening would be
needed to find the drivers in this region.
The connection between genetic events, genes, and biological
processes may provide insight into more general aspects of cervical
carcinogenesis. Several genes were often associated with a single
genetic event, supporting the hypothesis that there can be multiple
drivers of an event that coordinately promote tumor evolution
[11]. In cases of genes in the same biological process, like the anti-
apoptosis genes BIRC2 and BIRC3 on 11q22, a broad and
therefore efficient control of the process may be obtained. Hence,
BIRC2 and BIRC3 may play complementary roles in apoptosis
Figure 5. Genetic events, correlating genes, and biological
processes in carcinogenesis and chemoradioresistance of
cervical cancers. Recurrent and predictive gene dosage alterations,
correlating genes, and biological processes overrepresented among the
genes are listed. Only the genetic events associated with a process or
chemoradioresistance (*) are included; six of the recurrent alterations
are therefore not shown. The genes are ordered by DNA location.
Correlating genes connected to chemoradioresistance were associated
with clinical outcome both at the gene dosage and expression level and
validated in an independent patient cohort. Gains and losses are
indicated with red and green color, respectively.
doi:10.1371/journal.pgen.1000719.g005
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may impair hypoxia induced apoptosis [46,47]. In cases of genes
in different biological processes, such as metabolism (NDUFS1),
macromolecule transport (HRB), and transcription (SMARCAL1,
HDAC4) on 2q, the collective control of these processes through a
single event is likely to give a growth advantage that is selected for
in carcinogenesis. One or more genes in all biological processes
were affected in most tumors due to the high frequency of the
recurrent gene dosage alterations. All processes were therefore
probably important, and the control of them through gains and
losses seems to be a common feature of the disease.
The candidate driver genes represent novel biomarkers that
may be utilized in the handling of cervical cancers. Diagnostic
assessment of the biomarkers may help to understand the
evolutionary status and therefore the biology of the cancer in
individual patients. In particular, the predictive biomarkers may
be used in addition to tumor size for classification of patients into
risk groups in a personalized treatment regime. The biomarkers
also open for the possibility to specifically repress biological
processes in carcinogenesis by molecular targeting, and thereby
interfere with tumor evolution. The use of drugs to inhibit
translation by interaction with EIF-proteins has shown promising
results [48] and been suggested as a tool to target tumor hypoxia
[49]. The approach may be applied at all stages of the disease,
since the genetic events probably emerge early. Moreover,
improved outcome after chemoradiotherapy might be achieved
by targeting the predictive biomarkers. Hence, viral-mediated
delivery of RYBP has been shown to induce apoptosis in a number
of cancer cell lines [38], and could be a useful strategy for the
patients with loss of this gene.
Materials and Methods
Patients
A cohort of 102 patients was included for basic analyses to
identify gene dosage alterations with aCGH (97 patients), affected
transcripts with cDNA microarrays (100 patients), and to confirm
the affected transcripts with the Illumina method (52 patients)
(Table 1). An independent cohort of 41 patients was used to validate
relationships between gene expression and outcome with the
Illumina method (Table 1). All patients received external irradiation
and brachytherapy combined with adjuvant cisplatin and were
followed up as described previously [50]. Eighteen patients received
extended radiation field due to enlarged common iliac and para-
aortal lymph nodes. Progression free survival, defined as the time
between diagnosis and the first event of locoregional and/or distant
relapse,wasused asend point.Sixpatients died ofcausesnot related
to cancer and were therefore censored. Tumor samples were
collected at the time of diagnosis. One – four biopsies, approxi-
mately 56565 mm in size, were taken at different locations of the
tumor, immediately snap-frozen in liquid nitrogen and stored at
280uC until used for analyses. The study was approved by the
regional committee of medical research ethics in southern Norway,
and written informed-consent was achieved from all patients.
Array Comparative Genomic Hybridization
The aCGH experiments and generation of absolute gene dosage
profiles have been described previously for all 97 patients
(ArrayExpress accession no. E-TABM-398) [14]. The array slides
were produced at the Microarray Facility at the Norwegian
Radium Hospital and contained 4549 unique genomic BAC and
PAC clones that covered the whole genome with a resolution of
approximately 1 Mb. Genomic DNA was isolated from the
biopsies, labeled, and co-hybridized with normal female DNA to
the array slides. DNA from different biopsies of the same tumor
was pooled. The biopsies of all except two patients had more than
50% tumor cells in HE stained sections from the middle part of the
sample. Median tumor cell fraction was 70% (range 30–90%).
After array scanning, image analysis, spot filtering, and ratio
normalization, the GLAD algorithm was applied for ratio
smoothing and breakpoint detection [51].
Absolute gene dosages. The smoothed ratios were
transferred to absolute DNA copy numbers in GeneCount by
utilizing tumor ploidy data and correcting for the normal cell
content of the samples [14]. The tumor ploidy was determined
from a separate piece of the biopsy by flow cytometry, and tumor
cell fraction was estimated by the program prior to the copy
number calculations. The ploidy data and tumor cell fractions
have been presented previously [14]. The tumor cell fractions,
ranging from 27% to 84%, were in general lower than the results
based on HE stained sections, probably because the amount of
immune cells infiltrating the tumor parenchyma are difficult to
quantify by histological examination [14]. The copy numbers were
rounded off to the nearest integer values.
The absolute gene dosage profile of each tumor was generated by
dividing each copy number by the ploidy. A gene dosage of 1
therefore implied no change in the copy number. The gene dosage
thresholdsforscoring gainsandlosseswere1.1and 0.9,respectively,
taking into account an uncertainty in the ploidy measurement of
approximately 10%. For scoring high level amplification, a gene
dosage of 2.5 or higher; i.e. 5 DNA copies in diploid tumors, was
required. Homozygote deletions had a gene dosage of 0.
Intratumor heterogeneity. The intratumor heterogeneity in
the copy numbers was assessed by comparing the aCGH ratio
distributions of the possible heterogeneous regions with the
distributions of the adjacent homogeneous regions by ANOVA
analysis [14]. Totally 86 patients had a tumor cell fraction
sufficiently high for reliable detection of heterogeneity, and the
remaining eleven patients were excluded from this analysis. The
heterogeneous regions have been listed previously [14]. A
heterogeneity index was calculated for gains and losses
separately, as the number of heterogeneous cases relative to the
total number of cases with alteration at each DNA location. The
copy number of the heterogeneous region was 0.5 above (gain) or
below (loss) the nearest integer value.
The GeneCount method has been extensively validated based on
the cervical cancer samples included in this study and a cohort of 94
lymphoma samples [14]. In particular, we used lymphoma samples
to showthat theestimatedtumorcellfractionscorrelate significantly
with the highly accurate values determined by flow cytometry [14].
cDNA Microarrays
The cDNA microarray experiments have been presented
previously for 48 of the 100 patients [50]. The array slides were
produced at the Microarray Facility at the Norwegian Radium
Hospital and contained more than 12000 unique cDNA clones,
including most known oncogenes and tumor suppressor genes.
Total RNA was isolated from the biopsies, labeled, and co-
hybridized with reference RNA (Universal Human Reference
RNA, Stratagene, La Jolla, CA) to the array slides. RNA from
different biopsies of the same tumor was pooled. Only biopsies
with more than 50% tumor cells in HE stained sections were
utilized. Median tumor cell fraction was 70% (range 50–90%). All
hybridizations were performed twice in a dye-swap design
(ArrayExpress accession no. E-TABM-817). After array scanning,
image analysis, spot filtering, and ratio normalization, the average
expression ratios were calculated from the two data sets and used
in the further analyses. The gene expressions were mapped to the
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cDNA and genomic clones, as derived from Ensembl (http://
www.ensembl.org/Homo_sapiens/searchview).
Illumina Gene Expression Beadarrays
Results based on cDNA data were validated with Illumina gene
expression beadarrays in 52 of the patients subjected to aCGH
and in the independent cohort of 41 patients. HumanWG-6 v3
beadchips (Illumina Inc., San Diego, CA) with 48000 transcripts
were used. RNA was isolated from the biopsies as described above
and amplified using the Illumina TotalPrep RNA amplification kit
(Ambion Inc., Austin, TX) with 500 ng of total RNA as input
material. cRNA was synthesized overnight (14 hr), labelled, and
hybridized to the chips at 58uC overnight, according to the
standard protocol. The hybridized chip was stained with
streptavidin-Cy3 (AmershamTM, PA43001, Buckinghampshire,
UK) and scanned with an Illumina beadarray reader. The scanned
images were imported into BeadStudio 3.1.3.0 (Illumina Inc.) for
extraction, quality control, and quintile normalization. The
annotation file HumanWG-6_V3_0_R0_11282955_A was used.
Statistics
The recurrent gene dosage alterations were identified based on
a score that was calculated for each genomic clone by multiplying
the average gene dosage amplitude with its frequency [16]. Gains
and losses were considered in two separate procedures. Semi-
discrete data were used, for which amplitudes lower than 1.1 were
set to 1 when searching for gains and amplitudes higher than 0.9
were set to 1 when searching for losses. The score significance was
assessed by comparison to similar scores obtained after data
permutation [16], adjusting the p-value by a multiple testing
procedure to control the false discovery rate (FDR) [52].
Recurrent alterations with an FDR q-value ,5% were reported.
Gene dosage alterations associated with clinical outcome were
identified with the LASSO method in the Cox proportional
hazards model [53], as implemented in [54]. The LASSO is a
method for variable selection and shrinkage in regression models
when the number of covariates is larger than the number of
individuals. By performing shrinkage in addition to selection, the
LASSO is more stable than stepwise procedures where variables
are either retained or discarded from the model sequentially, one
at a time. In groups of highly correlated variables the LASSO
tends to select only one variable in the group [55], and reported
therefore one representative of each DNA region that jointly
explained the outcome. Each region was thereafter found by
selecting neighbouring genomic clones with strong correlation
(r.0.9) to the one reported. Survival curves were generated by
Kaplan-Meier analysis and compared by using log-rank test.
Spearman’s rank correlation analysis with an FDR q-value ,5%
was used to search for significant correlations between gene dosage
and expression. The analysis was based on semi-discrete data,
retrieved as described above. To identify biological processes that were
overrepresented among the correlating genes, the GO categories of
the genes were compared with those of all genes on the array by using
the master-target procedure with the Fisher’s exact test in the eGOn
software [15]. The GO categories were found in eGOn from public
databases, based on the gene reporter EntrezGeneID.
Supporting Information
Figure S1 Tumor ploidy and gene dosage alterations in relation
to histological type and HPV status. (A) Ploidy distribution of 97
patients. Tumors with a ploidy within the range of 1.8–2.2 were
considered as near diploid. (B) Ploidy of patients with adenosqua-
mous carcinoma or HPV negative tumor. (C, D) Frequency of
patients with gains (red) and losses (green) along chromosome 1 to
X for patients with adenosquamous carcinoma (C) and HPV
negative tumor (D). Gene dosage alterations above 1.1 and below
0.9 were classified as gains and losses, respectively. (A–D) Tumors
in the basic cohort subjected to aCGH analysis were included.
Found at: doi:10.1371/journal.pgen.1000719.s001 (0.30 MB TIF)
Figure S2 Tumor ploidy and gene dosage alterations in
homogeneous and heterogeneous tumors. (A) Ploidy distribution
of patients with homogeneous (left) and heterogeneous (right)
tumors. (B,C) Frequency of patients with gains (red) and losses
(green) along chromosome 1 to X for patients with homogeneous
(B) and heterogeneous (C) tumor. Gene dosage alterations above
1.1 and below 0.9 were classified as gains and losses, respectively.
Totally 86 patients with a tumor cell fraction sufficiently high for
reliable detection of heterogeneity were included in the analysis.
Found at: doi:10.1371/journal.pgen.1000719.s002 (0.29 MB TIF)
Figure S3 Clinical outcome for patients with different combi-
nations of predictive losses. Kaplan-Meier curves showing
progression free survival after chemoradiotherapy of 97 cervical
cancer patients with different combinations of 3p11.2-p14.1,
13q13.1-q21.1, and 21q22.2-3 loss. The different combinations
and number of patients in each group are listed (right). P-value in
log-rank test is indicated.
Found at: doi:10.1371/journal.pgen.1000719.s003 (0.24 MB TIF)
Figure S4 Correlations between gene dosage and expression.
Typical correlation plots of gene dosage and expression for 9
correlating genes within the recurrent and predictive regions; 6 with
gain and 3 with loss. Spearman’s rank correlation analysis on semi-
discrete data was performed, for which amplitudes lower than 1.1
were set to 1 for gains and amplitudes higher than 0.9 were set to 1
for losses. Correlation coefficient (R) and p-value are indicated.
Found at: doi:10.1371/journal.pgen.1000719.s004 (0.27 MB TIF)
Table S1 Recurrent high-level amplifications and homozygous
deletions in locally advanced cervical cancer.
Found at: doi:10.1371/journal.pgen.1000719.s005 (0.03 MB PDF)
Table S2 Relationships among Illumina, cDNA, and gene
dosage data for correlating genes.
Found at: doi:10.1371/journal.pgen.1000719.s006 (0.07 MB PDF)
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